Strata Skin Sciences Inc. (SSKN) filed a Form 8K – Director, Officer or Compensation Filing – with the U.S Securities and Exchange Commission on November 30, 2017.
On November 30, 2017, Christina Allgeier, Chief Financial Officer of Strata Skin Sciences, Inc., a Delaware corporation (the “Company”), upon mutual agreement with the Board of Directors, resigned from her position as the Company’s Chief Financial Officer, effective December 31, 2017 (the “Separation Date”). Ms. Allgeier will remain the Chief Financial Officer of the Company through the Separation Date. Ms. Allgeier has offered, and the Company has accepted her offer, to provide consulting services on a part-time basis to the Company through March 31, 2018, which may include, but not be limited to, (a) providing the Company with assistance and information necessary to the transition of Chief Financial Officer and other management job responsibilities; (b) providing assistance to and cooperation with the Company in locating information or data and providing other known information; (c) providing assistance to the Company in preparing and filing its Form 10-K for 2017; and (d) performing work on special projects identified by the Company. A written agreement reflecting these terms between the Company and Ms. Allgeier has not yet been executed.
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1051514/000105151417000080/form_8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/1051514/000105151417000080/0001051514-17-000080-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company’s financial position or the value of its shares.
Copyright (c) 2017 Dow Jones & Company, Inc.